One of India’s most well-known laboratory chains could soon start with the late-stage clinical trials of the Sputnik V COVID-19 vaccine that drew a lot of attention for the speed at which it was approved by the Russian state.
India’s Dr. Reddy’s lab could start the clinical trials in the next few weeks, Reuters reported, citing Deepak Sapra, CEO for API and pharmaceutical services at Dr. Reddy’s.
Up to 2000 candidates would be enrolled to test the efficacy of the Russian jab at different private and government hospitals.
Russia’s ‘Sputnik V’ vaccine garnered Western criticism for pulling short the usually long trajectory of approving the safety and efficacy of the vaccine.
“We want to get to the first step – which is the commencement of the clinical trials by getting the necessary approvals from the Indian regulators – within the next few weeks,” Sapra told Reuters news agency.
According to the report, if passed 100 million doses of the vaccine will be delivered to India, in a deal between the Russian Direct Investment Fund (RDIF) and Dr. Reddy’s.
Apart from India, Moscow confirmed its vaccine will be delivered to Saudi Arabia, Mexico, and Brazil.
Approving the vaccine for the Indian populations will be subjected to local regulations, and the RDIF has also reportedly reached in agreements with Indian manufacturers to make 300 million doses of the vaccine in the nation.
Just recently, Russia claimed it has received ‘expressions of interest’ for 1.3 billion doses of its Sputnik V vaccine from across 10 countries in the Middle East, South America, and Asia.
In the meantime, the US has declared it is unlikely for the nation to use either of the Chinese or Russian vaccines over skepticism in safety.
Wall Street Journal reported the Russian vaccine was jabbed only in 76 volunteers before passing it off as effective.
Experts claim large scale trial, which often involves tens of thousands of volunteers in regular cases, is imperative to determine the efficacy of a vaccine.
Reports also claim, Russia is getting ready to jab its own population with Sputnik V by the end of this year, while China has already injected hundreds of thousands of its inhabitants with locally made vaccines.